Compare WAFU & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAFU | NXL |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | China | United States |
| Employees | N/A | 7 |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 8.3M |
| IPO Year | 2017 | N/A |
| Metric | WAFU | NXL |
|---|---|---|
| Price | $1.63 | $0.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.0K | ★ 103.1K |
| Earning Date | 07-31-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $120.99 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $0.34 |
| 52 Week High | $2.17 | $2.31 |
| Indicator | WAFU | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 33.06 |
| Support Level | $1.39 | N/A |
| Resistance Level | $1.75 | $0.46 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 14.79 | 10.05 |
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions, and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.